Using ADNI data, we classified AD versus controls and MCI patients who progressed to AD within a year, against those who did not. The approach performed similarly to considering all data at once, while significantly reducing the number
(and cost) of the biomarkers needed BI 2536 in vivo to achieve a confident diagnosis for each patient. Thus, it may contribute to a personalized and effective detection of AD, and may prove useful in clinical settings.”
“A series of novel xanthone derivatives 6-16 having non-coplanar and flexible structures were synthesized as potent alpha-glucosidase inhibitors. Biological evaluation indicated that compounds 6-12 bearing one or two naphthol moieties exhibited up to 30-fold enhanced activities compared with their corresponding parent compounds 2-5, whereas compounds 13-16 bearing one dihydroxylnaphthalenyl group showed decreased activities compared with their corresponding analogs 6-9 having one naphthol group. Among them, compounds 7-8, 10-12 and 15 were more active than 1-deoxynojirimycin, a well-known inhibitor for alpha-glucosidase. The structure-activity correlations suggested that inhibiting of alpha-glucosidase was a result of multiple interactions with the enzyme, including pi-stacking, hydrophobic effect and conformational flexibility due to the structural non-coplanarity. In addition, Proteasome inhibitor compounds 4, 8 and 15 showed
non-competitive inhibition. (C) 2011 Elsevier Masson SAS. All rights reserved.”
“The 50th anniversary of Seminars in Hematology coincides with the 50th anniversary of St. Jude Children’s Research Hospital, and both milestones are inexorably linked to studies contributing to the cure of childhood acute lymphoblastic leukemia (ALL). We thought it fitting, therefore, to mark these events by traveling back in time to point out some of the achievements, institutions, study groups, and individuals that have made cure of childhood ALL a reality. In many instances, progress was driven by new ideas, while in others it was driven by new experimental tools that allowed more precise assessment of the biology of leukemic blasts and their utility in selecting therapy. We also discuss a number
Compound C of contemporary advances that point the way to exciting future directions. Whatever pathways are taken, a clear challenge will be to use emerging genome-based or immunologic-based treatment options in ways that will enhance, rather than duplicate or compromise, recent gains in outcome with classic cytotoxic chemotherapy. The theme of this journey serves as a reminder of the chief ingredient of any research directed to a catastrophic disease such as ALL. It is the audacity of a small group of investigators who confronted a childhood cancer with the goal of cure, not palliation, as their mindset. Semin Hematol 50:185-196. (C) 2013 Elsevier Inc. All rights reserved.”
“Objective: Markers of platelet activation are increased in patients undergoing cardiopulmonary resuscitation.